Advanced Search

    Technical Analysis for NVCT - Nuvectis Pharma, Inc.

    Grade Last Price % Change Price Change
    A 17.82 1.65% 0.29
    NVCT closed up 1.65 percent on Friday, June 9, 2023, on 1.27 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical NVCT trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing High Bullish 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Inside Day Range Contraction 1.65%
    Gapped Down Weakness 1.65%
    Pocket Pivot Bullish Swing Setup 1.37%
    Outside Day Range Expansion 1.37%
    Gapped Down Weakness 1.37%
    Overbought Stochastic Strength 3.73%
    Overbought Stochastic Strength 2.06%
    Older End-of-Day Signals for NVCT ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    New 52 Week High about 12 hours ago
    Up 1% about 13 hours ago
    2x Volume Pace about 13 hours ago
    1.5x Volume Pace about 13 hours ago
    10 DMA Support about 14 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NVCT Chart by TradingView
    Basic chart:

    Profile

    Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Life Sciences Biology Treatment Of Cancer Tyrosine Kinase Oncogenes Cancer Research Kinase Small Molecule Proto Oncogene Tyrosine Protein Kinase Src

    Is NVCT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 1 Zacks.com featured highlights Corsair Gaming, Nuvectis Pharma and WisdomTree
    May 31 3 Best Breakout Stocks Worth Buying for Superlative Returns
    May 15 Wall Street Analysts Think Nuvectis Pharma, Inc. (NVCT) Could Surge 29.35%: Read This Before Placing a Bet
    May 15 Nuvectis Pharma Announces FDA Clearance of NXP900 IND
    May 10 Nuvectis Pharma: Q1 Earnings Insights
    Apr 27 Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
    Apr 27 Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
    Apr 10 Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
    Apr 5 Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have recently purchased stock and their bets paid off last week as company hit US$198m market cap
    Mar 17 Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
    See more NVCT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.82
    52 Week Low 6.21
    Average Volume 38,319
    200-Day Moving Average 10.22
    50-Day Moving Average 15.44
    20-Day Moving Average 17.19
    10-Day Moving Average 17.50
    Average True Range 0.67
    RSI (14) 68.85
    ADX 27.25
    +DI 18.57
    -DI 11.56
    Chandelier Exit (Long, 3 ATRs) 15.82
    Chandelier Exit (Short, 3 ATRs) 16.60
    Upper Bollinger Bands 17.99
    Lower Bollinger Band 16.38
    Percent B (%b) 0.89
    BandWidth 9.37
    MACD Line 0.67
    MACD Signal Line 0.74
    MACD Histogram -0.0709
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 18.35
    Resistance 3 (R3) 18.29 18.05 18.26
    Resistance 2 (R2) 18.05 17.92 18.08 18.23
    Resistance 1 (R1) 17.94 17.84 18.00 18.00 18.20
    Pivot Point 17.70 17.70 17.73 17.73 17.70
    Support 1 (S1) 17.59 17.57 17.65 17.65 17.44
    Support 2 (S2) 17.35 17.49 17.38 17.41
    Support 3 (S3) 17.24 17.35 17.38
    Support 4 (S4) 17.30